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ac.uk (A.J. Williams).Mutations in RyR2 are causative of an inherited disorder which often results in sudden cardiac
death. Dysfunctional channel behaviour has been the subject of many investigations varying from
single channel analysis through to complex animal models. This review discusses recent advances
in the ﬁeld, describes the controversy surrounding the exact consequences of RyR2 mutation and
how the disparate data may be reconciled. This heterogeneity of function with respect to the effects
of polymorphisms, phosphorylation, cytosolic and luminal Ca2+ as well as inter-domain interactions
may have important implications for the recent pharmaceutical therapies which have been put for-
ward. We surmise that a comprehensive characterisation of mutations on a case-by-case basis may
be beneﬁcial for the development of speciﬁcally targeted therapies.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The contractile state of cardiac muscle is controlled by the level
of Ca2+ in the cytosol surrounding the contractile apparatus. On
depolarisation Ca2+ enters the cell through L-type channels of the
sarcolemma and this Ca2+ in turn initiates the release of more
Ca2+ from an intracellular storage organelle; the sarcoplasmic
reticulum (SR). The pathway for release is provided by a cation-
selective, ligand gated channel known, because it contains a high
afﬁnity binding site for the plant alkaloid ryanodine, as the cardiac
ryanodine receptor or ryanodine receptor2 (RyR2). Mutations in
the gene encoding RyR2 have been implicated in arrhythmogenicchemical Societies. Published by E
ergic receptor; cAMP, cyclic
dependent protein kinase;
ic polymorphic ventricular
r depolarisation; EC, excita-
y cAMP; FKBP12.6, 12.6 kDa
amino)ethyl]-5-isoquinoline-
ryonic kidney 293; HF, heart
se inhibitor 1; ICD, implant-
PKA, protein kinase A; PP1,
yR, ryanodine receptor; SCD,
, ventricular tachycardia; WT,
homas), williamsaj9@cardiff.disorders the most prevalent of which is catecholaminergic poly-
morphic ventricular tachycardia (CPVT); a potentially lethal herita-
ble syndrome which manifests as stress or exercise-induced
arrhythmia in the absence of any structural heart disease with a
normal resting sinus rhythm and electrocardiogram [1]. However,
under exercise-stress testing CPVT is pathognomonically identiﬁed
by bi-directional VT, which is thought to arise as a result of de-
layed-after depolarisations (DADs). These DADs in turn result from
inward, depolarising currents via the Na+/Ca2+ exchanger caused
by increased diastolic Ca2+ levels resulting from RyR2 mediated
leak from the SR [2]. This underlines the importance of RyR2 dys-
regulation in arrhythmogenesis, and has led to a number of studies,
through which we could potentially gain insight into the mecha-
nism of RyR2 dysfunction during arrhythmia in heart failure (HF)
as well as that underpinning CPVT. This review discusses the cur-
rent literature on mutant RyR2 characterisation, the various differ-
ent and contradictory proposed mechanisms and whether, in the
light of the ever increasing rate of mutation discovery and the
use of disparate characterisation methods, they are ever likely to
be reconciled and a ﬁtting therapy developed.
2. Clustering of RyR2 mutations and polymorphisms
RyR2 mutations have traditionally been thought to cluster into
three distinct regions or ‘hot-spots’ of the coding sequence (see
Fig. 1), corresponding to those in the skeletal isoform RyR1 knownlsevier B.V. All rights reserved.
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(MH) and central core disease. The signiﬁcance of this clustering
is not known, though it has been suggested that these N-, C-termi-
nal and central domains represent modulatory regions imperative
for channel function, possibly because they are adjacent to or in-
volved in intra-RyR2 interaction.
However, the rate of mutation discovery is ever increasing and
currently there are 124 substitutions, one insertion, one point dele-
tion and two genomic rearrangements, resulting in the deletion of
an entire exon (see [3]), known to be associated with SCD. Hence,
even though these are grouped broadly into three domains, there
are further ‘sub-domains’ forming and there is a blurring of the
‘hot-spot’ boundaries (see Fig. 1) with 45 of the 105 exons known
to contain at least one mutation.
There seems to be no correlation between the position of the
mutation or type of residue change with the severity of phenotype
[4]. In fact there seems to be a great deal of phenotypic heteroge-
neity between mutation carriers, and most cohorts contain a num-
ber of completely asymptomatic individuals. This could be
explained by environmental and genetic differences between indi-
viduals. In accordance with this it is known that genetic polymor-
phisms (i.e. base changes that are common in the general
population, which are not believed to cause any functional abnor-
malities) may modulate the expression, localization and function
of mutant ion channels [5–7]. These studies suggest that the vari-
able penetrance which seems to be present in Na+, K+ and Ca2+
channelopathies may arise due to ‘protection’ afforded by the
incorporation of interfering polymorphism-containing subunits
into the mutant channel structure. RyR2 is known to contain 15
polymorphisms [3,8], two of which are known to be inherited in
cis of mutations [9,10]. Unfortunately, the effects of these polymor-
phisms on mutant RyR2 function have not yet been thoroughly
characterised, though initial results from studies investigating
the effect of the G1885E polymorphism on the L433P CPVT muta-
tion do seem to suggest some modulation of mutant channel func-
tion [11] though further investigation is required. As well as having
a putative role in the modulation of mutant function, polymor-
phisms have also been shown to be associated with arrhythmia.
In particular, G1885E when inherited in a composite heterozygous
fashion with the G1886S polymorphism has been shown to result
in SCD [8]. Characterisation in a human embryonic kidney (HEK)
cell system demonstrated that G1885E/G1886S heterotetramers
show a signiﬁcantly decreased frequency of spontaneous Ca2+ re-
lease events compared to wild type (WT), similar to recently de-
scribed CPVT mutation (A4860G [12] see section below on the
effects of mutation on luminal Ca2+ sensitivity). Confusingly, these
polymorphisms expressed alone were shown to cause an increase
in cellular Ca2+ oscillation activity [13]. Thus, though it seems these
residues play an important role in RyR2 regulation, the precise ef-
fects on channel function and the interplay between the polymor-Fig. 1. The increasing distribution of CPVT mutational loci of hRyR2. Each residue of hRy
deletion/insertion; 2, mutated to two different amino acids). The mutational index (mean
plotted against residue X to provide a graphical representation of how the mutation-rich
present day.phisms remain to be resolved. In contrast, a recently reported
polymorphism (N3308S) found in a patient exhibiting ventricu-
lar premature complexes at rest and a history of syncope, was
functionally regulated (in terms of single channel Ca2+ activation)
in a similar manner to the WT [14], suggesting that this polymor-
phism is in fact benign and that the cause of arrhythmia lies
elsewhere.
While the potential signiﬁcance of RyR2 polymorphisms has
been recognised, the study of their putative functional effects is
still in its initial stages, and further investigation is anticipated.
3. The inﬂuence of phosphorylation on mutant channel
function: which kinase and at which site?
The consequences of RyR2 phosphorylation are still not well
established, and there has been much controversy regarding which
sites and kinases are important in determining functional changes
in health and disease. There are two main kinase contenders, the
most obvious being protein kinase A (PKA), as it is directly acti-
vated during stress-induced b-adrenergic stimulation [15], and
Ca2+-calmodulin dependent protein kinase (CaMKII) – a recent tar-
get in RyR2 mediated disease processes (recently reviewed in
[16,17]. Both of which have been proposed to phosphorylate the
channel at the same site: S2808 in the human sequence (equiva-
lent to S2809 in the rabbit sequence) [18,19], and at least one other
site each [20,21]. A signiﬁcant study was carried out by Marx et al.
[19] in which it was reported that PKA dependent phosphorylation
at S2808 increased the open probability (Po) of RyR2s, and destabi-
lised the channel promoting the occurrence of subconductance
states. The candidate mechanism being that PKA phosphorylation
caused displacement of 12.6 kDa FK506 binding protein
(FKBP12.6); this was later suggested as a common mechanism
for Ca2+ leak during HF and atrial ﬁbrillation (AF) [22,23].
Confusingly, CaMKII phosphorylation of this site did not pro-
duce these effects even though a phosphomimetic mutation at
the site in question (S2809D) resulted in subconductance states
and an increased Po compared to WT which coincided with a loss
of FKBP12.6 binding [20,24]. Subsequently, these authors demon-
strated that several recombinantly expressed RyR2 mutations, (in
regions distributed throughout the protein), exhibited a reduced
afﬁnity for FKBP12.6 following PKA phosphorylation and thus were
characterised by similar defective regulation [20,25]. Soon after,
both of these studies were contradicted by data showing that phos-
phorylation at S2808 did not affect FKBP12.6 binding [26,27], and
that aberrant Ca2+ release from mutant RyR2 was not associated
with FKBP12.6 dissociation [28,29]. Further contradiction has aris-
en from recent knock-in mouse models of CPVT, the ﬁrst of which
(R4496C+/, equivalent to R4497C in the human sequence) showed
that both the phosphorylation at S2808 [30] and the RyR2–
FKBP12.6 interaction were similar in cardiac SR from both WTR2 was scored according to mutational status (0, unmutated; 1, one point mutation/
score for each 100-amino-acid window, i.e. residue X+99 downstream residues) was
regions within the 4967-residue RyR2 polypeptide have increased from 2001 to the
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[31]. Likewise with another model (R176C+/), this was also the
case [32,33]. In contrast, a more recent mouse model (R2474S+/)
demonstrated a signiﬁcantly decreased level of FKBP12.6 binding
to mutant RyR2 which was accompanied by enhanced phosphory-
lation at S2808 under conditions of adrenergic drive [34]. This
could imply that these mutations cause dysfunction by different
mechanisms. Functional heterogeneity between mutants has been
suggested previously [35], and that this may have therapeutic
implications (see section below on intra-molecular interactions
and [36]).
In addition to this, the functional signiﬁcance of phosphoryla-
tion at S2808 has been questioned. Single channel studies by Carter
et al. [37] suggested that RyR2 is phosphorylated to 75% of its full
stoichiometry at S2808 under basal conditions, and that this repre-
sented the lowest level of channel activity. In line with this, it was
found that the b-adrenergic response and cellular function was not
altered in a mouse model where S2808 could not be phosphory-
lated (S2808A+/ [38]). Neither did this offer signiﬁcant protection
in the maladaptive cardiac remodelling induced by chronic stress,
suggesting that S2808 phosphorylation does not play a major role
in cardiac dysfunction [39]. Alternatively, S2808 phosphorylation
may enable RyR2 to become responsive to phosphorylation at other
sites, which may be of more physiological relevance in dynamic
channel modulation. Further to this, another PKA phosphorylation
site at S2030 (S2031 in the rabbit sequence) has been proposed as
a marker of enhanced b-adrenergic stimulation in cardiac disease
models [21], and single channel characterisation a S to A mutation
at 2030, but not 2808 reduced the activating effect of PKA [40], indi-
cating that this is the more relevant phosphorylation site.
Even though the PKA pathway has long been established as the
direct product of b-adrenergic stimulation, CaMKII activation in re-
sponse to sympathetic drive is now becoming more accepted as an
additional regulatory pathway [41–44] and interestingly CaMKII
has been found to phosphorylate RyR2 at an additional site;
S2814 (S2815 in the rabbit sequence) [45] and possibly others that
are as yet undiscovered [46]. Recent studies have also found that
CaMKII phosphorylation at this residue potently activates the
channel [44,47]. Consistent with this, inhibition of CaMKII was
found to block isoproterenol-induced SR Ca2+ leak, while inhibition
of PKA had no effect, signifying that abnormal phosphorylation by
CaMKII may be a key event in arrhythmogenesis [43]. CaMKII-
dependent phosphorylation was thought to occur via a cyclic aden-
osine monophosphate/PKA (cAMP/PKA) independent pathway
since stimulation of adenylate cyclase did not appear to affect leak.
To add further complexity, other authors propose that activation of
CaMKII is via PKA activation, since PKA inhibition with H-89 has
been shown to prevent phosphorylation at S2814 [44]. This sug-
gests that phosphorylation at this site by CaMKII requires the up-
stream activation of PKA. The most obvious interpretation of this
result is that CaMKII only becomes activated after PKA-induced in-
creases in Ca2+ transients, as has been previously surmised [48].
Alternatively, CaMKII activation could occur via suppression of
protein phosphatase type 1 by PKA-dependent phosphorylation
of its inhibitor I-1, since phosphorylation of S2814 was decreased
in I-1 KO mice [49]. PKA independent b-adrenergic receptor (b-
AR) activation of CaMKII via Epac (a guanine nucleotide exchange
protein activated by cAMP) has also been proposed. In fact, CaMKII
activation via Epac has also been shown to give rise to phosphory-
lation of RyR2 at S2814 [50]. Epac has also been shown to trigger
ventricular arrhythmias via a CaMKII mediated mechanism [51],
suggesting that this could play a role in CPVT. Even though there
has been some investigation into the role of CaMKII phosphoryla-
tion of RyR2 in HF [47,52], relatively little is known about its ef-
fects in CPVT. However, recent data from Chelu et al. [53] has
shown that a predisposition to AF in rapidly paced R176Q+/ micewas prevented by either pharmacologic or genetic inhibition of
CaMKII, implying that CaMKII plays a role in CPVT related
arrhythmogenesis. In spite of this, AF is not a typical symptom of
CPVT and has not been reported in patients harbouring this muta-
tion, and so the relevance of this result is not immediately clear.
Among other unexplored possibilities is the putative effect of
reactive oxygen species (ROS), released during catecholamine
induction [54], onmutant RyR2 function. Though it has been shown
that the redox sensitivity of FKBP12.6 binding was similar in mu-
tant and WT channels [55], redox modiﬁcation of RyR2 has been
implicated in SR Ca2+ leak in HF [56]. Interestingly, CaMKII can be
activated by ROS oxidation at M281/282 [57], suggesting that this
could also represent an avenue for the genesis of arrhythmia. How-
ever, the role of ROS in CPVT is completely undeﬁned. Similarly,
even though there have been numerous studies, controversies
and speculation on the subject, the effects of phosphorylation in
CPVT remains unclear. Recent reports have certainly shown that
mutants respond differently to phosphorylation, some showing
no response and others showing sensitised activation [58,59], signi-
fying that this may not be a common mechanism of dysfunction.4. Changes in sensitivity to cytosolic and luminal Ca2+, the most
obvious yet seemingly most complex mechanism of channel
dysfunction
Ca2+ is both the physiologically relevant permeant ion and pri-
mary agonist of RyR2, and recent data from the characterisation
of the R4496C+/ mouse model has pinpointed increased Ca2+ sen-
sitivity as a feature of mutant dysfunction, as demonstrated by
[3H] ryanodine binding and increased spark frequency in permeabi-
lised myocytes [30]. This was also reported by Yang et al. [60] who
found that peptide-induced disruption of the RyR2 structure (alleg-
edly corresponding to the effects of central domain mutation, see
section on interacting domains below) lowered the threshold for
cytosolic Ca2+ activation, resulting in sustained SR Ca2+ leak which
could trigger DADs. Moreover, sensitised Ca2+-dependent activa-
tion, such as that induced by low-dose caffeine, has been shown
to result in DADs in cardiomyocytes in the presence of b-AR stimu-
lation, suggesting that this is a plausiblemechanism for arrhythmo-
genesis [61]. Some mutants have been characterised as exhibiting
‘diastolic leak’ i.e. they show an increased open probability/release
event frequency compared to WT at low (sub-activating) cytosolic
Ca2+ concentrations, in the absence of kinase treatment (R3570W
[59], N4104K [62], R4496C [63] S4546R [58], N4895D [62]). How-
ever, the reasonwhy thesemutants in particular exhibit thismolec-
ular phenotype is unknown. Other mutations (R176Q/T2504M and
L433P) have been characterised as having a decreased sensitivity to
Ca2+-dependent channel inhibition, suggesting that mutation may
also affect deactivation mechanisms [64].
Despite this, it is well known that RyR2 is regulated by Ca2+ on
both cytosolic and luminal sides of the channel and increased
luminal Ca2+ sensitivity has been reported for CPVT mutants
[29,62]. In fact, most CPVT mutants have demonstrated this char-
acteristic to varying extents apart from one: A4860G, which was
shown to completely abolish luminal Ca2+ sensitivity [12]. This sig-
niﬁes that not all CPVT mutations act by a common mechanism of
channel dysfunction, and it is possible that different mutations
could have different effects.
Nevertheless, defective luminal sensing has been implicated as
pathological in the recessive form of CPVT resulting from muta-
tions in cardiac calsequestrin (CSQ2), a RyR accessory protein
thought to act as a luminal Ca2+ buffer and sensor [65]. Alterations
in CSQ2 arise from either nonsense mutations, which obviously
knock out protein expression completely [66], or missense muta-
tions [67] which appear to either affect the Ca2+ buffering ability
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luminal accessory protein triadin [65,68,69]. Interestingly, the pos-
sibility that RyR2 mutation affects interaction with these luminal
accessory proteins has not been investigated and so far it seems
unlikely that mutations in RyR2 and CSQ2 result in a common
mechanism of dysfunction. Data from CSQ2 mutant mouse models
indicate that all these types of mutation affect restitution of Ca2+
release from RyR2 and that CSQ2 seems to act as a ‘molecular
brake’, preventing inappropriate Ca2+ release [70,71].
In addition to the complexity of separating the effects of RyR2
mutation on luminal vs cytosolic Ca2+ activation, with and without
the contributory effects of accessory proteins, it is also speculated
that the effects of luminal activation play a role in determining the
consequences of phosphorylation, with PKA only having a stimula-
tory effect on Po in the presence of luminal activation [72]. Hence,
even though it is known that RyR2 mutation affects the channel’s
Ca2+ sensitivity this may be the product of several other effects
which may be extremely difﬁcult to tease apart.5. Channel inter-domain interactions and the use of peptides to
investigate channel dysfunction
It has been suggested that interactions between RyR2 tetramers
is important in the functional regulation of Ca2+ release (so called,
coupled gating [73]), and that disruption of these interactions is
predicted to result in arrhythmia [74]. However this has not yet
been shown to be a mechanism at work in the pathogenesis of
CPVT and remains to be investigated. In contrast, peptide studies
have revealed that interacting portions of RyR1 and RyR2 can be
disrupted by mutation, leading to channel instability and diastolic
leak [60,75] indicating that these interactions are essential in
maintaining channel closure, and may be involved in the confor-
mational changes involved in Ca2+ release. These studies demon-
strated that domain peptides corresponding to portions of the N-
terminal (residues 590–639) and central domain (residues 2460–
2495 (DPc10)) of RyR2 enhanced [3H]-ryanodine binding to and
Ca2+ release from cardiac SR. These peptides were also shown to
sensitise the channel to activating Ca2+, causing both increased
sensitivity of Ca2+ induced Ca2+ release and Ca2+ leak from the SR
in permeabilised myocytes [60]. These effects were attributed to
competitive binding of the central domain peptide to the N-termi-
nal of the channel (and conversely, binding of the N-terminal pep-
tide to the central domain of the channel), disrupting the intra-
molecular interactions that would normally stabilise the resting
state. These effects were abolished by introducing a CPVT mutation
(R2474S) into the central domain peptide, indicating that the mu-
tated residue was essential for interaction with the N-terminus and
thus channel regulation, and that defective interaction between
these domains may represent a pathological mechanism by which
defective RyR2 function could result in arrhythmia generation [75].
Indeed, unzipping of single channels by DPc10 has been shown to
cause an increase in sensitivity to cytoplasmic and, to a greater ex-
tent luminal Ca2+ sensitivity [76], mechanisms already proposed to
be at work in CPVT [29,30,64]. Cryo-electron microscopy studies of
the RyR2 tetramer have however implied a 30 Å distance be-
tween GFP tags inserted at S437 and S2367, implying that a direct
interaction of N-terminal and central domain mutation ‘hot-spots’
is unlikely [77,78], and conﬁrmation of the peptide binding sites
using cross-linking techniques (as for RyR1, [79]) would be invalu-
able. Recently, this peptide approach has been extended to other
RyR2 domains (residues 163–195 and 4090–4123, whose mutant
counterparts are R176Q and N4104K respectively), and disruption
of inter-domain interaction was shown by increased ﬂuorescence
quenching of labelled RyR2s (i.e. the quenching molecule has ac-
cess to the label due to unzipping) and increased SR Ca2+ leak[36]. However it seems that structural instability originating from
each of these different regions has different consequences, in par-
ticular with respect to the outcomes of drug treatment (see below).
Notably, the 4090–4123 peptide caused dysfunction which could
not be reversed on wash out, indicating a difference in mechanism.
Interestingly, this region, which precedes the trans-membrane
spanning domains, is considered functionally important in the
transduction of signals from the N-terminus of the channel to the
pore region [80]. Mutations occurring within this part of the
RyR2, termed the I-domain (interacting domain, residues 3722–
4610) promoted instability in both post-activation conformation
and Ca2+ release, as measured using ﬂuorescence resonance energy
transfer and Ca2+ imaging techniques. In accordance with the pep-
tide studies, this work also signiﬁed that mutations in the I-domain
give rise to more pronounced agonist-stimulated conformational
and Ca2+ release instability compared to mutations occurring out-
side this region [81]. This heterogeneity in response also has impli-
cations for drug therapy, where an anticipated ‘one ﬁts all’
approach may not be applicable.6. The emergence of new drug therapies for CPVT
CPVT is normally treated with b-blockers which, by virtue of
their action in reducing the effects of adrenergic drive under
stress/exercise, decrease the arrhythmogenic burden in patients –
however, they are not effective in a number of cases where there
is a persistent reoccurrence of tachyarrhythmias [82]. This group
of patients become candidates for implantable cardioveter deﬁbril-
lator (ICD) therapy which is mostly successful in preventing SCD,
despite a few documented cases where death has occurred despite
the device being in place [83,84]. In these cases, sympathetic
denervation has been proposed as a plausible alternative, espe-
cially since appropriate or inappropriate shocks can trigger further
adrenergic stress and arrhythmias [85]. However these strategies
are invasive and impose a tremendous cost implication, and so
the search for an effective, better targeted pharmaceutical solution
has begun.
An experimental drug, K201 (formerly known as JTV519) repre-
sents a promising advance in this area. This drug was proposed to
stabilise the RyR2:FKBP12.6 complex, thereby normalising cardiac
function [86,87]. However, the signiﬁcance of FKBP12.6 dissocia-
tion in CPVT is controversial and subsequent studies have indi-
cated that the mechanism by which K201 operates is FKBP12.6
independent. Hunt et al. [88] showed that treating ventricular
myocytes with FK506 to dissociate FKBP12.6 from RyR2 did not af-
fect the suppression of spontaneous Ca2+ release by K201. In addi-
tion, K201 inhibited [3H] ryanodine binding to WT and CPVT
mutant channels in the absence of FKBP12.6, suggesting that this
accessory protein is not required for the drug’s action. Another
study found that dissociation of FKBP12.6 from RyR2 actually in-
creased in the presence of K201, even though the effect of the drug
was to stabilise the channel [89]. In addition to its action on RyR2,
K201 has also been found to inhibit the SR Ca2+ ATPase [90], and it
may be this dual inhibitory action which makes K201 so effective.
In fact, K201 is a derivative of the benzothiazepine class of voltage-
gated Ca2+ channel blockers, and lacks speciﬁcity for RyR2 [91] and
it is feasible that the beneﬁcial effects of the drug may be attribut-
able to its lack of speciﬁcity. Despite this, K201 was found to have
no cardioprotective effect on catecholamine induced DADs and
arrhythmia generation in the R4496C+/ mouse model of CPVT
[31]. The reason for these discrepancies is not known, although a
recent study has demonstrated that K201 cannot correct defective
domain-domain interactions caused by mutations in the I-domain
region (the peptide used here corresponded to residues 4090–
4123), whereas those in the N-terminal and central domains can
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the binding site for K201 is localised in the central domain (resi-
dues 2114–2149; [92]), and is therefore removed from the site of
destabilization. However, these results are not in agreement with
previous experiments which showed that K201, albeit at a much
higher concentration, was able to alter the sensitised Ca2+ depen-
dent activation of an I-domain RyR2 mutant (N4104K) such that
it was similar to that of the WT channel [88]. Thus, K201 may
not be an effective therapy for the treatment of cardiac arrhyth-
mias resulting from these more severe mutations as the effective
concentration of K201 may be unachievable in vivo.
Another 1,4-benzothiazepine derivative, S107 is thought to
have higher speciﬁcity for RyR2 and has been shown to prevent
arrhythmias in R2474S+/ mice, once again by promoting binding
of FKBP12.6 [34]. This drug also decreased the frequency of epilep-
tic seizures seen in these CPVT knock-in mice, and improved exer-
cise capacity in a Duchenne muscular dystrophy mouse model
seemingly through stabilisation of RyR2 in the brain and RyR1 in
skeletal muscle respectively, once again by restoring the interac-
tion of FKBP12.6/12 with the channel [34,93]. Thus, this compound
seems to have many beneﬁcial effects, and it would be interesting
to see if this increase in speciﬁcity would be sufﬁcient to have an
effect on arrhythmogenesis in the R4496C+/ CPVT model. Other
candidate drugs include dantrolene, normally used to treat MH,
which is known to bind to RyR2 as well as RyR1 at a site in the
N-terminus of the peptide sequence (residues 601–620) and was
shown to inhibit diastolic Ca2+ release and DADs in a dog model
of HF by rectifying the unzipped state of the channels as well as
those treated with central domain CPVT mimicking peptides [94].
Another candidate is verapamil, which has already been used in
combination with b-blockers with some success in treating CPVTTable 1
Summary of the characterisation of R2474S and R4497C CPVT mutants. Noticeably, the tw
same mutation has been shown to give contradictory results depending on the system of
Mutation R2474S
Knock-in mouse
phenotype and
response to drug
treatment
Mice underwent spontaneous tonic–clonic seizures, exerci
catecholamine induced arrhythmias and SCD (8/9 tested). T
with S107 prevented arrhythmia [34]
Results from cell
systems
Enhanced store overload induced Ca2+ release (SOICR) com
HEK cells expressing WT mRyR2 [62]
Effects of PKA
phosphorylation
Sensitised cytosolic Ca2+ activation compared to WT [20]
Effect on FKBP12.6 Afﬁnity for FKBP12.6 (hRyR2) co-expressed in HEK cells de
even in the absence of phosphorylation [20]
% FKBP12.6 bound to mutant mRyR2 was not signiﬁcantly
compared to WT, though afﬁnity was not calculated [29]
Single channel studies Po under diastolic conditions* and Ca2+ activation not sign
different to WT before phosphorylation [12]
Po at low Ca2+** not signiﬁcantly different compared to WT
increased luminal Ca2+ sensitivity [29]
Peptide studies DPc10 (2460–2495) caused domain unzipping and increas
the sensitivity of Ca2+ induced Ca2+ release and Ca2+ leak fro
in a permeabilised myocyte system [60]
DPc10 increased cytoplasmic and, to a greater extent lumi
sensitivity but did not affect luminal Ca2+ sensing directly
increase in sensitivity was reliant on current ﬂow in the lu
cytoplasmic direction [76]
* Diastolic conditions refers to 150 nM Ca2+ and 1 mM Mg2+ in the cis compartment w
** Low Ca2+ refers to symmetrical 45 nM buffered Ca2+.[95]. Verapamil is traditionally not thought to affect RyR2 directly,
being classiﬁed as an L-type Ca2+ channel blocker. It is likely that
any effects seen are due to an indirect effect on RyR2 as a conse-
quence of a reduction in Ca2+ inﬂux during the action potential.
However, it has been proposed to affect RyR2 function in CPVT pa-
tients [96] and has in fact been shown to bind directly to RyR and
to decrease the open probability of the channel [97]. Recent studies
have shown that CPVT patients resistant to treatment with verap-
amil and b-blockers could be treated successfully with ﬂecainide
[98], a cardiac Na+ channel antagonist now thought to block
RyR2 [99]. This drug was tested in a CSQ2/ model of CPVT, in
which it decreased the frequency of arrhythmogenic Ca2+ waves
without altering the SR Ca2+ load. Analysis of sparks in rat cardio-
myocytes revealed that ﬂecainide achieved this by actually
increasing the frequency of these elementary events, but decreas-
ing their amplitude and width. Single channel investigations dem-
onstrated that ﬂecainide treatment seemed to increase the
frequency of closing events, resulting in a decrease in the mean
open time, without changing the closed duration. Further to this,
and in contrast to K201 and S107, this drug appeared to induce a
subconductance state, suggesting that it physically blocks the con-
duction pathway of the channel. However, all recordings were car-
ried out at positive holding potentials (with the current ﬂowing
from cytoplasm to lumen), and as it is likely that under the exper-
imental conditions used ﬂecainide will be in its ionised and there-
fore charged state, it is possible that these direct effects of
ﬂecainide on the channel may have been exaggerated. This signi-
ﬁes a need for the effects of ﬂecainide to be conﬁrmed by further
investigation in other CPVT models and on mutant RyR2 channels.
Another concern is ﬂecainide’s potential pro-arrhythmic effects
in HF patients with VT [100], and the fact that is has beeno different mutations sometimes have profoundly different effects. Furthermore, the
characterisation.
R4497C
se/
reatment
Mice developed arrhythmias upon exercise/catecholamine
treatment (5/14 tested). K201 treatment failed to prevent
arrhythmia [31]
pared to Enhanced SOICR compared to HEK cells expressing WT mRyR2,
increased activity at low [Ca2+]c as assessed by [3H] ryanodine
binding [63]
Increased sensitivity of response of hRyR2 to physiological and
pharmacological agonists in HL-1 cells [28]
Increased sensitivity of Ca2þc activation as measured by [
3H]
ryanodine binding from knock-in mice [30]
Sensitised activation compared to WT. Also, notably the diastolic Po
signiﬁcantly increased compared to WT [20]
creased Afﬁnity for FKBP12.6 decreased (hRyR2) co-expressed in HEK cells
even in the absence of phosphorylation [20]
different FKBP12.6 in microsomal fraction was comparable to WT hRyR2 in
HL-1 cells either before or after isoproterenol stimulation [28]
RyR2–FKBP12.6 interaction in knock in mouse model is identical to
the WT both before and after epinephrine and caffeine treatment
[31]
iﬁcantly Po under diastolic conditions* and Ca2+ activation not signiﬁcantly
different to WT before phosphorylation [20]
, but Po at low Ca2+ (<100 nM) signiﬁcantly increased compared to WT,
Ca2+ activation however not signiﬁcantly different in terms of EC50,
but increased luminal Ca2+ sensitivity [62,63]
ed both
m the SR
DP4090–4123 caused domain unzipping and increased spark
frequency and SR Ca2+ leak when introduced into cardiomyocytes.
K201 did not suppress these effects [36]
nal Ca2+
as the
minal to
ith 53 mM trans Ca2+.
2158 N.L. Thomas et al. / FEBS Letters 584 (2010) 2153–2160documented to have been prescribed for CPVT in a previous study,
where it was withdrawn since it resulted in an increased incidence
of syncope [101]. Thus, it may be that the efﬁcacy of ﬂecainide, like
K201 is possibly genotype-dependent and it could be that the bio-
physical properties of individual mutant channels are important in
determining the therapeutic response, as with LQT3 mutant Na+
channels [102].
7. Conclusion
The characterisation of mutant RyR2s is a burgeoning area of
cardiac research, nevertheless due to the fast rate at which new
mutations are discovered (a recent publication recently revealed
a further 34 [3]) currently only 14% have been investigated. An-
other observation we make is that even the most investigated
mutations (R4497C and R2474S) result in some degree of func-
tional heterogeneity with respect to the effects of phosphorylation
and Ca2+ sensitivity (see Table 1), depending on the channel spe-
cies and the use of different animal, cellular, and in vitro based
techniques and it is noteworthy that not all of these aspects have
been investigated within the same study. It had seemed plausible
that the structural instability caused by domain unzipping could
represent a primary mechanistic event in channel dysfunction
and that all other effects (e.g. increased sensitivity to cytosolic/
luminal Ca2+ etc) occur as a result of this, however as the muta-
tional regions expand to cover 43% of the peptide sequence it be-
comes less likely that all mutations could result in unzipping, and
some may even promote abnormally ‘tight’ domain–domain inter-
action [103].
More importantly, this functional heterogeneity may play an
important role in determining the efﬁcacy of the newly emerging
drug treatments and it is possible that ‘mutation-speciﬁc’ therapies
may have to be developed. It is possible that we may gain valuable
information in this respect by acquiring the crystal structure of the
channel, and indeed this has been achieved for the ﬁrst 217 amino
acids [104]. This study has demonstrated that two mutations con-
tained within this sequence (A77V and V186M) cause distinct local
changes in the surface of the protein, and it is expected that the
coalescence of such structural information with detailed functional
data will enable us to gain a comprehensive understanding of mu-
tant channel dysfunction and lead to better targeted therapies.
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